Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
Can Taltz® (ixekizumab) be used in Patients with COVID-19?
Lilly has not studied the use of ixekizumab in patients with comorbid COVID-19 nor in patients at risk of contracting COVID-19.
Ixekizumab Infection-Related Warnings and Precautions according to the SmPC
Taltz is contraindicated in patients with clinically important active infections (e. g. active tuberculosis) and should be used in caution in patients with clinically important chronic infection or a history of recurrent infection.1 For complete information, please refer to the Taltz Summary of Product Characteristics, in particular the sections1:
- 4.3 Contraindications
- 4.4 Special warnings and precautions for use
Below, you will find further information about Ixekizumab in patients with suspected or confirmed COVID-19.
Ixekizumab Treatment in Patients with Suspected or Confirmed COVID-19
Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.2
- If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.2
- If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.2
Use of Ixekizumab in High Risk Areas
At this time, Eli Lilly and Company has not studied the use of ixekizumab in patients at risk of contracting COVID-19.
The decision on treatment remains at the discretion of prescribing physician.
COVID-19
COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal.2
Infectious Disease Resources
For the most current information regarding the coronavirus, please refer to the World Health Organization (WHO) website:
References
1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland [UK]
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.
Date of Last Review: 03 March 2023